Glucagon-like peptide-1 (GLP-1) receptor agonists now serve as therapeutic agents forcardiovasculardiseases(CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM). This review combines molecular mechanisms with clinical evidence to demonstrate howGLP-1agonists help lowercardiovascularrisk for conditions, including atherosclerosis, heart failure, stroke, and ...
New research has shown thatGLP‑1weight-loss drugs deliver protection against heart attacks, strokes, and premature death over a sustained period of time. Researchers from Anglia Ruskin ...
Quick Takes Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) forcardiovascularrisk reduction and their broader impacts on cardiometabolic health beyond diabetes mellitus management, guided by the latest clinical trial findings and guidelines. Clinicians should be vigilant for gastrointestinal tract adverse effects in patients using ...
This particular example perfectly highlights why Palmitate Glp-1 Cardiovascular Disease is so captivating.
Despite the extensive research onGLP-1RAs in blood glucose control and alleviation of diabetes complications, there remains a significant gap in research regarding their broader effects, especially concerningcardiovascularprotection and other potential therapeutic benefits.
The protective role of glucagonlike peptide-1 (GLP-1) and its analogs incardiovasculardiseasehas been suggested by both preclinical and clinical studies (12).
Cardiovascularoutcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed thecardiovascularbenefits of glucagon-like peptide1receptor agonists (GLP-1RAs), including reducedcardiovascularmortality, lower rates of myocardial infarction, and lower rates of stroke. Thecardiovascularbenefits observed followingGLP-1RA treatment could be secondary to ...
